IDXX
IDEXX LABORATORIES INC /DE
Key Financials
Net Income
$1.1B
↑ 19.3%
Revenue
$4.3B
↑ 10.4%
Gross Profit
$2.7B
↑ 11.8%
Operating Income
$1.4B
↑ 20.5%
Total Assets
$3.4B
↑ 1.7%
Total Liabilities
$1.7B
↑ 2.8%
Cash & Equivalents
$180.1M
↓ 37.5%
Shareholders' Equity
$1.6B
↑ 0.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| ARS | 3/27/2026 | View on SEC |
| DEFA14A | 3/27/2026 | View on SEC |
| DEF 14A | 3/27/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 8-K | 3/26/2026 | View on SEC |
| PRE 14A | 3/13/2026 | View on SEC |
| 4 | 3/5/2026 | View on SEC |
| 4 | 3/5/2026 | View on SEC |
| 4/A | 3/3/2026 | View on SEC |
| 144 | 3/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IDXX |
| Company Name | IDEXX LABORATORIES INC /DE |
| CIK | 874716 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 2075560300 |